Huntington Study Group Launches Project AWARE 2.0 Observational Study
The Huntington Study Group® and HSG Clinical Research, Inc. (together, “HSG”) are pleased to announce the launch of Project AWARE 2.0, an observational study developed in collaboration with Roche Products Limited and Genentech to understand and improve Awareness, Willingness, and... - April 10, 2024
Huntington Study Group Announces 2024 Annual Meeting
The Huntington Study Group® (HSG), together with its wholly owned subsidiary, HSG Clinical Research, Inc., a world leader in conducting clinical trials for Huntington’s disease (HD), is pleased to announce that its annual meeting for 2024 is slated to take place from November 6-9 at the... - January 22, 2024
Huntington Study Group and Roche Collaborate on GENERATION HD2 Study
The Huntington Study Group together with its wholly-owned clinical research organization, HSG Clinical Research, Inc. (HSGCR), is pleased to announce a collaboration with Roche-Genentech to optimize our collective experiences in Huntington’s disease (HD) clinical research. Together we are... - December 13, 2023
Huntington Study Group® Holds 30th Annual Meeting
The Huntington Study Group® (HSG®), a world leader in conducting clinical trials and providing educational programming for Huntington’s disease (HD), recently held its 30th annual meeting, HSG 2023, November 2-4 in Phoenix, AZ. Hundreds of scientists, industry partners, HSG research... - November 21, 2023
Huntington Study Group® Observational Pilot Study Shows HSG’s myHDstory® Platform Reaches the Unreachable
The Huntington Study Group® (HSG) together with its wholly owned subsidiary, HSG Clinical Research, Inc. (HSGCR), a world leader in conducting clinical trials for Huntington’s disease (HD), today announces that the pilot observational study on their innovative online direct-to-patient... - October 16, 2023
Huntington Study Group Welcomes FDA Approval of New Drug for Chorea in Huntington’s Disease
The Huntington Study Group (HSG) together with its wholly owned subsidiary, HSG Clinical Research, Inc., a world leader in clinical trials for Huntington’s disease (HD), today shares that the Phase 3 pivotal KINECT®-HD study conducted by HSG in collaboration with Neurocrine Biosciences,... - August 18, 2023
Huntington Study Group Announces Positive Topline Results for Virtual Unified Huntington’s Disease Rating Scale® (vUHDRS®) Study
The Huntington Study Group (HSG) together with its wholly owned subsidiary, HSG Clinical Research, Inc., a world leader in conducting clinical trials for Huntington’s disease (HD), today announces positive topline results from its Virtual Unified Huntington’s Disease Rating Scale®... - August 14, 2023
Huntington Study Group and CHDI Foundation Collaborate on Enroll-HD
HSG Clinical Research, Inc. - the Huntington Study Group’s clinical research organization (CRO) and wholly owned subsidiary (collectively referred to here as HSG) - has begun providing CRO services for CHDI Foundation’s Enroll-HD observational study and clinical research platform in the... - July 25, 2023
Huntington Study Group Announces Call for Abstracts for 30th Annual Meeting
The Huntington Study Group (HSG), with a mission of accelerating treatments that make a difference for those impacted by Huntington’s disease, together with its wholly owned subsidiary, HSG Clinical Research, Inc., a world leader in conducting clinical trials for Huntington’s disease... - June 01, 2023
Neurocrine Biosciences Announces Publication of Full KINECT™-HD Phase 3 Study Results of Valbenazine
Neurocrine Biosciences Announces Publication of Full KINECT™-HD Phase 3 Study Results of Valbenazine for the Treatment of Chorea Associated with Huntington’s Disease in The Lancet Neurology. - Statistically Significant Improvement in Chorea Associated with Huntington’s Disease... - May 19, 2023
Huntington Study Group Achieves Last Patient Last Visit for Its Observational Study to Test Virtual Use of the Unified Huntington’s Disease Rating Scale®
The Huntington Study Group (HSG) together with its wholly owned subsidiary, HSG Clinical Research, Inc., announces an important milestone in the novel observational study Virtual Unified Huntington’s Disease Rating Scale (vUHDRS™). The last participant completed the last visit, marking... - May 16, 2023
HSG and HD-CAB Collaborate to Provide Global Patient Advisory Board
The Huntington Study Group (HSG) together with its wholly owned subsidiary, HSG Clinical Research, Inc., a world leader in conducting clinical trials for Huntington’s disease (HD), recently collaborated with Huntington’s Disease – Community Advisory Board (HD-CAB) to provide a... - March 30, 2023
HSG Announces 30th Annual Meeting
The Huntington Study Group (HSG), a world leader in conducting clinical trials and providing educational programming for Huntington’s disease (HD), recently announced that their 2023 Annual Meeting will be held November 2-4, 2023 at the Sheraton Grand at Wild Horse Pass in Chandler, AZ, a... - March 21, 2023
Huntington Study Group Names First Chief Innovation Officer
The Huntington Study Group (HSG), a world leader in clinical research for Huntington’s Disease (HD) for over 30 years, today announced Brett Kinsler has been named to the newly created position of Chief Innovation Officer (CINO). - January 10, 2023
Clinical Research Organization, Huntington Study Group “Firsts” Continue
The Huntington Study Group (HSG), a world leader in conducting clinical trials for Huntington’s Disease (HD) through its Clinical Research Organization (CRO), HSG Clinical Research, Inc. (HSGCR) continues making groundbreaking progress in the HD world. At their Annual Meeting in November, the... - December 05, 2022
Huntington Study Group Annual Meeting
The Huntington Study Group (HSG), a world leader in conducting clinical trials for Huntington’s Disease (HD), recently held its 29th Annual Meeting in Tampa, FL. This renowned meeting brings together HD thought leaders, scientific experts, industry partners and sponsors, advocacy groups, and... - November 29, 2022
Huntington Study Group Announces Results from the HD-Net Assessment on the State of Care for Huntington’s Disease in the United States
The Huntington Study Group (HSG), a world leader in clinical research for Huntington’s Disease (HD) for over 30 years, is pleased to announce the results from the novel HD-Net survey, which examined the United States Huntington’s disease (HD) care delivery in a variety of clinic settings by HD specialists and non-specialists. - October 25, 2022
Huntington Study Group Announces myHDstory™ Pilot Study: Making HD Voices Heard Has Reached Target Enrollment
The Huntington Study Group (HSG), a world leader in clinical research for Huntington’s Disease (HD) for over 30 years, is pleased to announce that the pilot study, Making HD Voices Heard, on the new online research platform, myHDstory™, has reached its enrollment target. “The HSG... - October 18, 2022
Huntington Study Group Enrolls First Participant for Its Observational Study to Test the Reliability of the Virtual Use of the Unified Huntington’s Disease Rating Scale
The Huntington Study Group (HSG), a world leader in conducting clinical trials for Huntington’s Disease (HD) for over 30 years, together with its Clinical Research Organization (“CRO”), the HSG Clinical Research, Inc., today announces the enrollment of the first participant of its... - October 12, 2022